DDInter666 DDInter1676
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Eribulin {u} (Compound) treats {v} (Disease) breast cancer
Eribulin {u} (Compound) binds {v} (Gene) TUBB
Eribulin {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Eribulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Verapamil
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paliperidone
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Eribulin (Compound) treats breast cancer (Disease)
Eribulin (Compound) binds TUBB (Gene)
Eribulin (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Eribulin may cause a minor interaction that can limit clinical effects when taken with Verapamil
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
Eribulin may lead to a major life threatening interaction when taken with Escitalopram